ELIGARD KIT Drug Patent Profile

When do Eligard Kit patents expire, and what generic alternatives are available?

Eligard Kit is a drug marketed by Tolmar and is included in four NDAs. There are three patents protecting this drug.

This drug has thirty patent family members in twenty-five countries.

The generic ingredient in ELIGARD KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eligard Kit

A generic version of ELIGARD KIT was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for ELIGARD KIT

International Patents:	30
US Patents:	3
Applicants:	1
NDAs:	4

US Patents and Regulatory Information for ELIGARD KIT

ELIGARD KIT is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021731-001	Dec 14, 2004		RX	Yes	Yes	11,771,841		Y	Y
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	11,771,841		Y	Y
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes	11,931,559			Y
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes	11,771,841		Y	Y

International Patents for ELIGARD KIT

See the table below for patents covering ELIGARD KIT around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2022137182
Australia	644581
Portugal	1267965
Norway	911277
New Zealand	525210	Polymeric delivery formulations of leuprolide with improved efficacy
Canada	2079831	COMPOSITION POLYMERIQUE BIODEGRADABLE (BIODEGRADABLE POLYMER COMPOSITION)
Spain	2241876

Supplementary Protection Certificates for ELIGARD KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0436667	C300204	Netherlands
0436667	91193	Luxembourg		91193, EXPIRES: 20140927

ELIGARD KIT: Investment Scenario and Fundamentals Analysis

Last updated: April 24, 2026

What is ELIGARD KIT and how is it used clinically?

ELIGARD KIT is a branded, physician-administered leuprolide acetate depot therapy formulated as a syringe kit for androgen deprivation therapy (ADT). In practice, it is used to reduce testosterone in men with prostate cancer, aligning with standard leuprolide-based treatment of hormone-sensitive disease and related settings.

Core positioning

• Drug class: GnRH (LHRH) agonist / ADT
• Active ingredient: leuprolide acetate
• Form: kit delivering a sustained-release depot after preparation/administration

What is the market access and evidence basis underpinning demand?

ELIGARD KIT’s commercial durability is tied to two fundamentals: clinical acceptability of leuprolide-based ADT and broad prescriber familiarity with depot formulations.

Demand drivers

• Prostate cancer incidence and chronic, recurring treatment pathways that sustain ADT consumption
• Established reimbursement pathways for ADT injectables
• Preference patterns for depot therapies that reduce dosing frequency versus daily oral alternatives

Key competitive reality

• In ADT, differences among leuprolide products often come down to dose schedule, dosing convenience, contracting, and supply reliability rather than transformative clinical differentiation. The “kit” format functions mainly as a delivery and convenience construct within a well-trodden molecule class.

How competitive is ELIGARD KIT within ADT, and what does that imply for pricing power?

ELIGARD KIT competes within a crowded ADT landscape that includes other leuprolide formulations and other ADT agents (including GnRH antagonists and alternative depot technologies). For investors, the key question is not whether ADT demand exists, but whether ELIGARD KIT can sustain gross-to-net levels and share in the face of:

• more aggressive contracting by competitors,
• pharmacy benefit management dynamics,
• and lifecycle pressure from new depot entrants or shifting guideline use.

Implications for pricing

• ADT pricing power typically compresses over time through rebates, channel incentives, and tender-like dynamics.
• Product-level differentiation is often narrower than the market’s therapeutic category breadth, so long-run economics depend more on net price resilience and volume retention than on premium clinical claims.

What are the financial fundamentals to evaluate for an ELIGARD KIT investment case?

A defensible fundamentals model for ELIGARD KIT must track three P&L drivers and two risk drivers.

Profit engine (what moves revenue)

1. Volume of administered doses
   • Patient starts
   • Persistence and regimen changes
   • Share-of-dose within leuprolide depots and across ADT options
2. Net pricing
   • List price is less informative than realized net after rebates, discounts, and contracting
3. Product/channel mix
   • Dose strengths and schedule (where applicable in the broader ELIGARD line)
   • Institutional versus office administration split

Risk engine (what breaks the model)

1. Supply continuity
   • Depot injectables face manufacturing and fulfillment exposure; a supply disruption impacts both revenue and payer confidence.
2. Competitive displacement
   • Loss of formulary position can materially shift net demand.

What is the patent and exclusivity landscape that matters for valuation?

For valuation of an “ELIGARD KIT” investment case, the critical inputs are:

• Composition-of-matter and formulation/process patent status tied to leuprolide acetate depot delivery
• Exclusivity periods (where relevant) tied to regulatory approval milestones
• Paragraph IV and other ANDA challenges risk around leuprolide depot variants, if applicable to the specific kit SKU(s)

In ADT, even when patents exist for formulation or manufacturing, the market often sees competitive entry on a schedule that compresses net price. Investors should anchor expected revenue to the timing of:

• generic or authorized-generic entry risk,
• label-expansion opportunities (if any),
• and substitution probabilities after formulary shifts.

What is the investment scenario under three base cases?

Base Case 1: “Steady share, contracting pressure”

Assumptions consistent with mature ADT products:

• ELIGARD KIT maintains relative share within leuprolide depots
• Realized net price trends down with standard gross-to-net compression
• Volume grows in line with underlying prostate cancer treatment demand

What to expect in outcomes

• Revenue grows modestly or remains flat in nominal terms depending on net price erosion
• Margins compress gradually as contracting intensifies

Base Case 2: “Formulary headwinds”

Assumptions:

• Competitors increase contracting pressure
• Switching to other ADT depot options or other leuprolide equivalents occurs

What to expect

• Share loss drives revenue contraction even if category demand rises
• Higher promotional and contracting costs reduce profitability

Base Case 3: “Supply or execution event”

Assumptions:

• Depot product continuity is disrupted
• Practice sites alter ordering patterns, creating longer recovery windows

What to expect

• Revenue step-down with delayed rebound
• Re-establishment of trust with payers and sites can take quarters

What are the key diligence checkpoints before underwriting?

An institutional-grade underwriting workflow for ELIGARD KIT should confirm:

• Unit economics: net price trajectory, rebate rates, and margin durability for the kit SKU(s)
• Channel performance: institutional agreements versus office purchase patterns
• Real-world utilization: dose administration frequency, persistence, and regimen switching
• Manufacturing reliability: batch release metrics, backorder history, and mitigation plans
• Regulatory status: label scope, contraindications, and any safety communications that affect prescribing behavior

How does ELIGARD KIT fit into portfolio strategy for ADT exposure?

ELIGARD KIT is best viewed as an ADT “share and net price” bet rather than a high-innovation catalyst.

Portfolio roles

• Stability sleeve: ADT is recurrent and guideline-driven, supporting cashflow visibility when supply is stable and contracting is manageable.
• Risk-managed exposure: valuation should be anchored to net price and volume rather than to pipeline optionality.
• Competitive hedging: if an investor holds multiple ADT exposures, ELIGARD KIT’s relative performance depends on channel contracting and formulary coverage.

Key Takeaways

• ELIGARD KIT is a leuprolide acetate ADT depot kit positioned inside a mature, crowded prostate cancer hormonal therapy market.
• The investment case turns on net pricing durability, dose-volume retention, and formulary stability, not on breakthrough clinical differentiation.
• Competitive pressure in ADT makes gross-to-net and share preservation the dominant fundamentals for underwriting.
• Patent-driven protection matters, but valuation must align to realistic timelines for entry and substitution risk across depot ADT products.
• Supply execution is a material downside driver because depot therapies are sensitive to fulfillment disruption and recovery time.

FAQs

1) Is ELIGARD KIT a long-cycle recurring revenue product?

Yes. ADT for prostate cancer involves ongoing therapy cycles, and depot dosing is designed for persistence in treatment regimens.

2) What drives ELIGARD KIT revenue most: price or volume?

Both matter, but in mature ADT categories realized net price and share-of-dose typically determine outcomes more than list price.

3) What competitive threats are most relevant to ELIGARD KIT?

Formulary contracting by other leuprolide depots and other ADT mechanisms can drive substitution and net price compression.

4) How important is supply reliability for depot kits like ELIGARD?

High. Depot products depend on continuous manufacturing and timely distribution; disruptions can cause longer-than-expected revenue recovery.

5) What is the main diligence focus for investors?

Validate the realized economics by SKU: net price, rebates, channel mix, administration volumes, and supply continuity, then map those to patent and entry timelines.

---

References

[1] FDA. Eligard prescribing information (leuprolide acetate) (accessed via FDA labeling repository).
[2] FDA. Drug Approval Reports / labeling documentation for leuprolide acetate depot products (accessed via FDA databases).
[3] National Comprehensive Cancer Network (NCCN). Prostate cancer guideline updates (ADT use and hormonal therapy frameworks; accessed via NCCN publications).
[4] EMA. Summary of Product Characteristics for leuprolide acetate formulations used in ADT (accessed via EMA product information).